GANX
Overvalued by 71.6% based on the discounted cash flow analysis.
Market cap | $48.56 Million |
---|---|
Enterprise Value | $32.79 Million |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.71 |
Beta | 1.17 |
Outstanding Shares | 18,051,979 |
Avg 30 Day Volume | 119,407 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.18 |
---|---|
PEG | -205.92 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 594.28 |
Enterprise Value to EBIT | -1.47 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | 0.08 |
No data
No data
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...